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Abstract
Background: We investigated the effects of lifetime cumulative ginseng intake on cognitive function in a
community-dwelling population-based prospective cohort of Korean elders.
Methods: Community-dwelling elders (N= 6422; mean age = 70.2 ± 6.9 years, education = 8.0 ± 5.3 years, female = 56.8%)
from the Korean Longitudinal Study on Cognitive Aging and Dementia were included. Among them, 3918 participants
(61.0%) completed the 2-year and 4-year follow-up evaluations. Subjects were categorized according to cumulative ginseng
intake at baseline evaluation; no use group, low use (< 5 years) group, and high use (≥ 5 years) group. One-way analysis of
covariance (ANCOVA) was conducted to compare the impact of cumulative ginseng intake on baseline Consortium to
Establish a Registry for Alzheimer’s Disease Assessment Packet neuropsychological battery total score (CERAD total score)
and Mini-Mental State Examination (MMSE) score among the three groups while adjusting for potential covariates. A
repeated-measures ANCOVA was performed to investigate the impacts on the changes in CERAD total scores and MMSE
scores during the 4 years of follow-up.
Results: The high use group showed higher CERAD total scores compared to the no use group after controlling for age,
sex, education years, socioeconomic status, smoking, alcohol intake, presence of hypertension, stroke history, Geriatric
Depression Scale, Cumulative Illness Rating Scale, and presence of the APOE e4 allele (F(2, 4762) = 3.978, p= 0.019). The
changes of CERAD total score for 2 or 4 years of follow-up did not differ according to the use of ginseng.
Conclusions: Cumulative ginseng use for longer than 5 years may be beneficial to cognitive function in late life.
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Background
Ginseng, which has been used for at least 2000 years in
Asian countries [1], is one of the most widely sold medi-
cinal herbs worldwide [2]. The estimated world ginseng
market is dramatically increasing, worth approximately
$2085 million in 2009 [1]. An analysis of the Korean
Ministry of Food and Drug Safety in the year 2015 re-
ported that ginseng products, including red ginseng and
white ginseng, reached KRW 725.0 billion, with the
highest market share reaching 39.8% of the dietary supple-
ment market in South Korea.
Ginseng is popular because it is effective in boosting
immune function, it has antifatigue effects, and it im-
proves cognitive functions [3]. Ginseng has the potential
to slow cognitive decline in elderly individuals or reduce
the risk of dementia, which is of great scientific and
public health interest. Biological data suggest that vari-
ous functional constituents, especially ginseng saponins
(also known as ginsenosides), improve brain cholinergic
function, decrease inflammation, and reduce production
of amyloid beta proteins that directly limit the progres-
sion of Alzheimer’s disease (AD) pathology [4–7].
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Recently, four randomized control trials (RCTs) [8–11]
of patients with AD revealed that red ginseng might be
effective for cognitive improvement. Among the four
RCTs, one study reported that the cognitive functions of
AD patients improved and were maintained with both
4.5 g/day and 9.0 g/day of red ginseng supplements dur-
ing 2 years of follow-up [10]. However, a systematic re-
view and meta-analysis [12] based on these four RCTs
concluded that the findings regarding the effects of
ginseng on AD were inconclusive due to the limita-
tions of these studies, which included small sample
sizes and lack of placebo control design. In terms of
participants without dementia, a systematic review
published in 2010 [2], which was based on the results
of nine double-blind RCTs, showed that there is in-
sufficient evidence regarding the efficacy of ginseng
on cognitive function due to limited sample sizes and
only short-term follow-up (up to 12 weeks).
Due to their inherent design characteristics, RCTs
cannot sufficiently reflect long-term ginseng intake;
therefore, the effects of long-term ginseng intake on
cognition should be studied in a longitudinal pro-
spective cohort. To our knowledge, the only instance
of such a study is the one by Persson et al. [13], a
prospective cohort study in Sweden that reported no
association between long-term ginseng use and
cognitive performance. However, the participants in
that study were aged 35–80 years, therefore making
it difficult to assess the effects of ginseng on the eld-
erly population. Additionally, the study was con-
ducted in a western country, where ginseng intake is
generally lower than it is in Asian countries. Among
3500 participants, 86 subjects (2.5%) had previously
used ginseng; therefore, if the effect size was small,
the effect of ginseng would be difficult to observe.
The study focused on revealing the relationship
between long-term ginseng intake and memory func-
tion, but there was no follow-up evaluation showing
the trajectory of cognitive performance over time.
There is still little research regarding how ginseng
usage correlates with cognitive function in elderly popu-
lations with and without cognitive impairment, and we
also have little information on the longitudinal effects of
ginseng. Furthermore, to our knowledge, a large popula-
tion cohort has never been studied in Asia, especially
not in Korea, where the amount of ginseng distribution
is the highest worldwide [1].
In this study, we investigated the correlation between
lifetime cumulative use of ginseng and cognitive function
in a large, community-dwelling, population-based pro-
spective cohort of elders in Asia, especially in Korea. In
addition, we sought to determine the effect of cumulative
ginseng intake on cognitive function during a follow-up
period of 4 years.
Methods
Subjects
This study was conducted as a part of the Korean
Longitudinal Study on Cognitive Aging and Dementia
(KLOSCAD), which is a population-based prospective
cohort study of Korean elders aged 60 years and older
[14]. Among the random sample (N = 12,694) drawn
from Koreans, 6818 participants completed an evalu-
ation of cognitive function during the baseline study
period, between 2010 and 2012 (response rate = 53.7%).
Participants with partial or no information regarding
neuropsychological tests, with a diagnostic deferral due
to comorbid major depressive disorder or intellectual
disability, or with no information regarding ginseng
intake were excluded (N = 396; Fig. 1). As a result, 6422
participants (mean age = 70.2 ± 6.9 years, education = 8.0
± 5.3 years, female = 56.8%) were eligible for baseline
analyses. Follow-up evaluations were conducted every
2 years, and the present study included the first and sec-
ond follow-up studies, obtained during 2012–2014 and
2014–2016, respectively. Of the 6422 subjects included
in this study, 3918 participants (61.0%) completed the
first and second follow-up evaluations. All participants
were fully informed of the study protocol and provided
written informed consent, signed by the subjects them-
selves or their legal guardians. The study protocol was
approved by the Institutional Review Board of the Seoul
National University Bundang Hospital.
Cumulative ginseng intake
At each evaluation, the age at initial ginseng intake and
the number of days in a month of ginseng intake (i.e.,
(1) white ginseng or (2) red ginseng in any formula con-
taining ginseng extract) were recorded using a question-
naire. Because the amount of ginseng varies considerably
between ginseng products and there is a low probability
of obtaining the exact amount of ginseng in any given
product, we defined “cumulative ginseng intake” by sub-
tracting the age at initial ginseng intake from the age at
study entry, adding 1 year to reflect the intake of the
first year, and then multiplying the result by a year’s
value of intake, calculated by multiplying the number of
days of ginseng intake in a month by 12 months. As the
median of the years of cumulative ginseng intake in par-
ticipants with ginseng consumption was 5 years, ginseng
use was categorized as “no use,” “low use” (< 5 years), or
“high use” (≥ 5 years).
Diagnostic assessments of cognitive disorders and
comorbid conditions
Geriatric neuropsychiatrists with expertise in dementia
research administered a face-to-face standardized diag-
nostic interview as well as physical and neurological ex-
aminations, using the Korean version of the Consortium
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to Establish a Registry for Alzheimer’s Disease Assessment
Packet Clinical Assessment Battery (CERAD-K-C) [15] to
diagnose cognitive disorders. Comorbid mental disorders,
including depressive disorders, were evaluated using the
Korean version of the Mini International Neuropsychiatric
Interview (MINI-K) [16, 17]. Research neuropsychologists
or trained research nurses administered the Korean
version of the Consortium to Establish a Registry for
Alzheimer’s Disease Assessment Packet Neuropsycho-
logical Assessment Battery (CERAD-K-N) [15, 18]. The
CERAD-K-N consists of nine neuropsychological tests: (1)
the Verbal Fluency Test, (2) the 15-item Boston Naming
Test, (3) the Mini Mental Status Examination for demen-
tia screening (MMSE-DS) [19], (4) the Word List Memory
Test, (5) the Constructional Praxis Test, (6) the Word List
Recall Test, (7) the Word List Recognition Test, (8) the
Constructional Recall Test, and (9) the Trail Making Test
A/B [15, 18]. The CERAD total score was calculated by
summation of CERAD-K-N subtest scores, excluding the
MMSE score [20].
Dementia was diagnosed according to the diagnostic
criteria in the Diagnostic and Statistical Manual of
Mental Disorders, fourth edition (DSM-IV) [21]. Mild
cognitive impairment (MCI) was diagnosed according to
12,694 subjects randomly selected 
6,818 completed baseline evaluation
Excluded, n=396
Diagnostic defer of cognitive status due to comorbid MDD (3), 
Intellectual disability (3)
No information on ginseng intake (297)
No or partial information on neuropsychological tests (93)
6,422 eligible for baseline analysis
3,918 completed second follow-up 
evaluation (4 years)
Lost in the first follow up, n=1,427
Died (168)
Refused or failed to participate (1,259)
3,803 (CERAD total score) and 3,808 (MMSE score) 
eligible for 4-year follow-up analysis
Lost in the second follow up, n=1,077
Died (141) 
Refused or failed to participate (936)
4,995 completed first follow-up 
evaluation (2 years)
Excluded due to missing value of
CERAD total score, n=115
MMSE score, n=110
either first or second follow-up evaluation
Fig. 1 Enrollment and follow-up of study participants. CERAD Consortium to Establish a Registry for Alzheimer’s Disease, MDD major depressive
disorder, MMSE Mini-Mental State Examination
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the Consensus Criteria from the International Working
Group on MCI [22]. The presence of objective cognitive
impairment was ascertained when the performance of
the subjects was − 1.5 standard deviations (SDs) or
below the mean age, gender, and education-adjusted
values in any of neuropsychological tests.
Sociodemographic factors, lifestyle factors, and comorbid
illnesses
Sociodemographic factors included age, sex, years of
education, and socioeconomic status (SES). The SES
was defined using medical insurance status, which
was categorized into two groups: medical insurance
group and Medicaid/Medicare group. Duration of
smoking (years), amount of smoking per day (in order
to calculate number of pack-years), and amount of al-
cohol consumption in units over the lifetime were re-
corded. Body mass index (BMI) was calculated by
dividing weight by the square of height (expressed in
kg/m2). Presence of hypertension or history of stroke
was identified by self-report or electronic database,
and the burden of comorbid illnesses was identified
using the Cumulative Illness Rating Scale (CIRS) [23].
Depressive symptom severity was assessed using the
Korean version of the Geriatric Depression Scale
(GDS-K) [24].
Statistical analyses
A one-way analysis of variance (ANOVA) for continuous
variables and a linear-by-linear test for categorical vari-
ables were used to compare the baseline sociodemo-
graphic and clinical characteristics between the no use,
low use, and high use groups for cumulative ginseng in-
take. Post-hoc analysis using the Bonferroni method was
performed. A one-way analysis of covariance (ANCOVA)
was conducted in order to compare the impact of cumu-
lative ginseng intake on baseline CERAD total and
MMSE scores across the three groups (no use, low use,
and high use) while adjusting for age, sex, years of
education, SES, smoking (pack-years), alcohol intake
(units in lifetime), presence of hypertension, stroke his-
tory, GDS-K, CIRS, and presence of APOE e4 allele.
Ordinal logistic regression using the generalized linear
model was conducted in order to compare the impact of
cumulative ginseng intake on the baseline clinical diag-
nosis while adjusting for the same confounding variables
as those of the ANCOVA model.
To investigate of the impacts of cumulative ginseng in-
take on changes in CERAD total and MMSE scores from
baseline to the first (2 years) and second (4 years)
follow-up evaluations, repeated-measures ANCOVAs
were performed with time and group as independent
factors and age, sex, years of education, SES, smoking
(pack-years), alcohol intake (units in lifetime), presence
of hypertension, stroke history, GDS-K, CIRS, presence
of the APOE e4 allele, and ginseng intake amount during
4 years as covariates. Analyses were performed with
SPSS software (version 23.0; SPSS, Chicago, IL, USA).
Results
Baseline characteristics according to cumulative ginseng
intake
At baseline evaluation, among 6422 participants, 677 sub-
jects (10.6%) had ever used ginseng. The low use group
(below median, < 5 years) included 491 subjects, and the
high use group (above median, ≥ 5 years) included 186
subjects (Table 1). The mean age of the no use group
(70.4 ± 7.0 years) was significantly higher than that of the
low use group (68.6 ± 6.0 years; F = 16.3, p < 0.001). Men
(11.3%) were more likely to take ginseng than women
(10.0%). Subjects with higher use (i.e., low use group vs no
use group, high use group vs low use group) showed lower
percentages of women (p < 0.001), had more years of
education (F=85.185, p < 0.001), and were more likely to be
in a higher SES group (p < 0.001). The BMI of the no use
group (24.1 ± 3.1) was significantly higher than that of the low
use group (23.7 ± 2.9; F=5.138, p=0.006). The group with no
use of ginseng showed higher GDS-K scores (10.2 ± 6.6) than
that of the low use group (9.3 ± 6.3) and high use
group (8.5 ± 5.9; F = 8.770, p < 0.001). Subjects in the
high use group had higher CIRS scores (5.2 ± 3.0)
than those of the no use group (4.5 ± 2.8) and low
use group (4.8 ± 2.8; F = 7.453, p = 0.001).
There were no differences in smoking habits, alcohol
intake, rate of hypertension, stroke history, and presence
of the APOE e4 allele relative to lifetime cumulative gin-
seng intake.
Impact of cumulative ginseng intake on the baseline
neuropsychological performance
The low use group showed higher CERAD total scores
than those of the no use group, and the high use group
showed better scores than the others (F= 47.049, p < 0.001;
Table 2). The low use and high use groups showed
higher MMSE-DS scores than the no use group (F =
32.825, p < 0.001). There was a significant effect of
cumulative ginseng intake on CERAD total score after
controlling for covariates, including age, sex, years of
education, SES, smoking, alcohol intake, presence of
hypertension, stroke history, GDS-K, CIRS, and presence
of the APOE e4 allele (F(2, 4762) = 3.978, p = 0.019). A
post hoc test showed that the high use group had higher
CERAD total scores than the no use group (p = 0.018).
However, there was no difference in MMSE-DS scores be-
tween the groups after adjusting for the covariates men-
tioned earlier.
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Impact of cumulative ginseng intake on the baseline
clinical diagnosis
Percentage of cognitive impairment (MCI or demen-
tia) was significantly higher in the low use group
(27.1%) than in the high use group (24.7%), and was
also higher in the no use group (32.6%) than in the
other groups (p < 0.001; Table 3). However, after
controlling for potential covariates which might have
influenced baseline clinical diagnosis, low use or high
use of cumulative ginseng intake did not decrease the
ordered log odds of being in a higher level of diagnosis
(higher level, normal cognition (NC) <MCI < dementia;
high use, B = − 0.201, standard error = 0.1993, p = 0.312;
low use, B = − 0.032, standard error = 0.1247, p = 0.800;
Table 3).
Impact of cumulative ginseng intake on cognitive
trajectory
Among the 6422 participants, 3918 subjects (61.0%)
completed both the first and second follow-up evalua-
tions (Fig. 1). During the first follow-up study, 168 par-
ticipants (2.6%) died and 1259 participants (19.6%)
refused or failed to participate in the follow-up for either
an unknown reason or institutionalization. Excluding the
Table 1 Sociodemographic and clinical characteristics among groups divided according to cumulative ginseng intake











p valuea Post hocb
Cumulative ginseng intake (years) 0.46 ± 2.28 0.0 1.85 ± 1.26 11.0 ± 7.21 < 0.001 0 < 1 < 2
Cumulative ginseng intake (amounts) 166.3 ± 820.8 0.0 663.4 ± 404.2 3989.7 ± 2595.7 < 0.001 0 < 1 < 2
Age (years) 70.2 ± 6.92 70.4 ± 7.0 68.6 ± 6.0 69.7 ± 5.9 < 0.001 0 > 1
Female, n (%) 3649 (56.8) 3316 (57.7) 252 (51.3) 81 (43.5) < 0.001
Education (years) 8.0 ± 5.3 7.7 ± 5.3 9.7 ± 5.1 11.9 ± 4.8 < 0.001 0 < 1 < 2
SES (medical insurance), n (%) 6186 (95.0) 5529 (94.8) 472 (95.4) 185 (98.9) 0.024
BMI (kg/m2)c 24.1 ± 3.1 24.1 ± 3.1 23.7 ± 2.9 23.7 ± 2.7 0.006 0 > 1
Smoking (pack-years)c 10.5 ± 29.8 10.7 ± 30.9 9.6 ± 18.2 8.9 ± 16.7 0.575
Alcohol intake (units in lifetime)c 1.3 × 104 ± 4.2 × 104 1.3 × 104 ± 4.3 × 104 1.3 × 104 ± 3.1 × 104 1.5 × 104 ± 3.1 × 104 0.768
Presence of hypertension, n (%) 3399 (52.9) 3046 (53.0) 252 (51.3) 101 (54.3) 0.869
Stroke history, n (%) 508 (7.9) 463 (8.1) 34 (6.9) 11 (5.9) 0.174
APOE e4 carrier, n (%)c 1215 (23.3) 1058 (22.9) 119 (27.9) 38 (22.8) 0.186
GDS-Kc 10.1 ± 6.6 10.2 ± 6.6 9.3 ± 6.3 8.5 ± 5.9 < 0.001 0 > 1, 0 > 2
CIRSc 4.5 ± 2.8 4.5 ± 2.8 4.8 ± 2.8 5.2 ± 3.0 0.001 0 < 2
Data shown as mean ± standard deviation for continuous variables
BMI body mass index, CIRS cumulative illness rating scale, GDS-K Korean version of the Geriatric Depression Scale, SES socioeconomic status
aDerived from one-way analysis of variance for continuous variables, from a linear-by-linear association test for categorical variables
bPost-hoc analysis using Bonferroni; 0, 1, and 2 denote nonusers, low ginseng intake group (< 5 years), and high ginseng intake group (≥ 5 years) respectively
cMissing values: BMI, n = 482; smoking, n = 62; alcohol intake, n = 52; APOE e4 carrier, n = 1212; GDS-K, n = 237; CIRS, n = 2
Table 2 Impact of cumulative ginseng intake on baseline CERAD total and MMSE-DS scores


















CERAD total score 60.2 ± 14.9 64.8 ± 12.3 68.1 ± 10.8 47.049* 0 < 1 < 2
62.3 ± 13.6 65.9 ± 11.7 68.5 ± 10.7 3.978** 0 < 2
MMSE-DS score 25.2 ± 4.2 26.3 ± 3.1 27.0 ± 2.2 32.825* 0 < 1, 0 < 2
25.9 ± 0.043 26.1 ± 0.139 26.2 ± 0.221 1.174
Data shown as mean ± standard deviation for analysis of variance (ANOVA), adjusted mean ± standard error for analysis of covariance (ANCOVA)
CERAD Consortium to Establish a Registry for Alzheimer’s Disease, MMSE-DS Mini-Mental State Examination for dementia screening
*p < 0.001; **p = 0.019
aPost-hoc analysis using Bonferroni; 0, 1, and 2 denote no-users, low ginseng intake group (< 5 years), and high ginseng intake group (≥ 5 years) respectively
bANCOVA adjusted for age, sex, years of education, socioeconomic status, body mass index, smoking (pack-years), alcohol intake (units in lifetime), presence of
hypertension, stroke history, Korean version of Geriatric Depression Scale, Cumulative Illness Rating Scale, and presence of APOE e4 allele
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1427 participants (22.2%) lost in the first follow-up
study, 1077 subjects (16.8%) were additionally lost dur-
ing the second follow-up period because 141 (2.2%) died
and 936 (14.6%) refused or failed to participate in the
second follow-up. Among the 3918 participants who
completed the first and second follow-up evaluations,
participants with missing CERAD total scores and
MMSE-DS scores at either first or second follow-up
evaluations were excluded, leaving 3803 and 3808 partic-
ipants for use in a repeated-measures ANOVA (RMA-
NOVA) of CERAD total scores and MMSE-DS scores,
respectively.
There was significant group effect (F = 19.974, p <
0.001) and time effect (F = 7.505, p = 0.001) in the
repeated-measures ANOVA for the CERAD total score,
but no significant time and group interaction (F = 0.361,
p = 0.837). For the MMSE score, the group effect was
significant (F = 14.526, p < 0.001), but there was neither
significant time effect (F = 0.304, p = 0.738) nor time and
group interaction (F = 0.951, p = 0.433; Fig. 2).
After controlling for age, sex, years of education, SES,
smoking, alcohol intake, presence of hypertension,
stroke history, GDS-K, CIRS, presence of APOE e4
allele, and amount of ginseng intake during 4 years in
the repeated-measures ANCOVA model, there was no
group effect for CERAD total score and MMSE score (F
= 1.060, df = 2.0, p = 0.346 for CERAD total score; F =
0.220, df = 2.0, p = 0.800 for MMSE). Although signifi-
cant time effects were shown for both CERAD total
score (F = 58.002, p < 0.001) and MMSE-DS score (F =
20.165, p < 0.001), there was no significant time and
group interaction for either CERAD total score (F =
1.653, p = 0.159) or MMSE-DS score (F = 0.667, p =
0.613; Table 4).
Discussion
The purpose of this study was to determine whether or
not lifetime cumulative ginseng intake has beneficial ef-
fects on cognitive function and future change. Here, we
found that individuals with high lifetime cumulative gin-
seng intake showed higher CERAD total scores in late
life than nonusers, even after comprehensively control-
ling for confounding variables that could affect cognitive
function. However, changes in cognitive function over 2
or 4 years in late life were not influenced by the use of
ginseng. To our knowledge, this study is the first that
Table 3 Impact of cumulative ginseng intake on baseline clinical diagnosis
Baseline clinical diagnosis, n (%) p valuea Ordinal logistic regression p valueb
NC MCI Dementia B SE 95% CI
Ginseng < 0.001
No use 3870 (67.4) 1610 (28.0) 265 (4.6) (Reference)
Low use (< 5 years) 358 (72.9) 124 (25.3) 9 (1.8) −0.032 0.1247 (− 0.276, 0.213) 0.800
High use (≥ 5 years) 140 (75.3) 45 (24.2) 1 (0.5) −0.201 0.1993 (− 0.592, 0.189) 0.312
Total 4368 (68.0) 1779 (27.7) 275 (4.3)
CI confidence interval, MCI mild cognitive impairment, NC normal cognition, SE standard error
aDerived from a linear-by-linear association test
bDerived from ordinal logistic regression using generalized linear model adjusted for age, sex, years of education, socioeconomic status, body mass index,
smoking (pack-years), alcohol intake (units in lifetime), presence of hypertension, stroke history, Korean version of Geriatric Depression Scale, Cumulative Illness
Rating Scale, and presence of APOE e4 allele
Table 4 Impact of cumulative ginseng intake on cognitive trajectory over 4 years
CERAD total score (N = 3084)a F value p valueb MMSE-DS (N = 3080)c F value p valueb
Baseline 2-year 4-year Baseline 2-year 4-year
Ginseng 1.062 0.346 0.223 0.800
No use 64.9 ± 12.2 65.8 ± 13.4 66.1 ± 14.3 26.3 ± 3.1 26.2 ± 3.4 26.3 ± 3.5
Low use (< 5 years) 68.0 ± 10.9 69.4 ± 11.6 69.5 ± 12.0 27.0 ± 2.4 27.0 ± 2.5 27.0 ± 3.0
High use (≥ 5 years) 70.3 ± 10.3 70.9 ± 10.3 70.5 ± 11.0 27.2 ± 1.8 27.5 ± 2.0 27.1 ± 2.2
time 58.002 < 0.001 20.165 < 0.001
Group × time 1.653 0.159 0.667 0.613
Data shown as mean ± standard deviation
CERAD Consortium to Establish a Registry for Alzheimer’s disease, MMSE-DS Mini-Mental State Examination for dementia screening
a719 from 3803 subjects excluded due to missing values of covariates
bp value in repeated-measures analysis of covariance model adjusting for age, sex, years of education, socioeconomic status, body mass index, smoking (pack-years),
alcohol intake (units for lifetime), presence of hypertension, stroke history, Korean version of geriatric depression scale, cumulative illness rating scale, presence of APOE
e4 allele, and ginseng intake amount during 4 years
c728 from 3808 subjects excluded due to missing values of covariates
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showed the effect of ginseng on late life cognitive func-
tion in a large, randomly sampled, community-based
elderly cohort.
These results indicate that long-term use of ginseng
may be beneficial to late life cognitive function.
The beneficial effect of ginseng on cognitive function was
dose dependent. The individuals who had taken ginseng for
more than 5 years showed better cognitive function than
those who never took ginseng, whereas those who had
taken ginseng for less than 5 years did not. There was no
previous study that delineated the duration of intake that
has efficacy on cognitive function in elderly populations.
Many of the previous RCTs [25–27] of ginseng effect on
cognitive performance were conducted with healthy
volunteers who were young or middle-aged, and duration
of intake ranged from days to several weeks in either 200
mg or 400 mg amounts. They suggested that ginseng might
improve some aspect of cognitive function; however, the
short duration of these studies and the inclusion of young
subjects limited the interpretations of results regarding
whether or not ginseng has longlasting effects on cognition,
even with a short duration of intake in aged groups. Of
course, some RCTs have also shown that high-dose (at least
4.5 g/day or 9.0 g/day), long-term (for 6 months or 2 years)
ginseng intake in AD patients has an effect on cognitive
function [10, 11]. However, ginseng dietary supplements do
not contain such a high dose. Various commercialized gin-
seng products contain at most 1 g/day. There has been only
one study exploring the effect of ginseng intake based on a
prospective cohort study that reflects real-world settings. In
the study by Persson et al. [13], which compared 86 ginseng
users (including 51 participants who used ginseng for over
2 years and 35 participants who used ginseng for 5.6 months
on average) and nonusers, no group difference was ob-
served, which is consistent with our findings that the low
use group (mean duration of cumulative ginseng intake
a
b
Fig. 2 Change in (a) CERAD total score and (b) MMSE-DS score at baseline, 2 years, and 4 years. *p < 0.01 for group effect at each time point in
model for repeated-measures ANOVA. CERAD Consortium to Establish a Registry for Alzheimer’s Disease, MMSE Mini-Mental State Examination,
yr year
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1.85 ± 1.26 years) did not show any significant difference in
CERAD total score compared to the no use group.
A beneficial effect of ginseng on cognitive function
was not observed in the 4-year prospective observation.
The cognitive changes over 4 years were comparable be-
tween the subjects who had taken ginseng for 5 years or
more at baseline and those who had never taken gin-
seng. This was the case when we additionally accounted
for the use of ginseng during the follow-up period in the
analysis. This discrepancy between the cross-sectional
and prospective analyses may be attributable to several
causes. First, the follow-up period may be too short to
show the beneficial effects of ginseng on cognitive func-
tion. Second, the subjects who responded to the
follow-up evaluations had better cognitive function at
baseline than those who did not and thus were less likely
to show cognitive decline over a short period. The data
are presented in detail in Additional file 1: Table S1.
Therefore, it may be beneficial to follow the subjects for
a longer period of time.
It is not yet well understood how ginseng improves cog-
nitive reserve (or brain reserve) [28]. Some previous stud-
ies showed that ginsenosides were protective against AD
pathologies: antioxidative effects, inhibition of Aβ-induced
cytotoxicity and tau phosphorylation, immunomodulatory
activities on intracellular signaling pathway, cell apoptosis,
and mitochondrial function [5, 6]. These neuroprotective
and compensatory effects of ginseng may directly and in-
directly contribute to cognitive reserve, resulting in better
baseline CERAD total score in individuals who consumed
ginseng over 5 years.
Although there were less cognitive disorders (i.e.,
MCI or dementia) in the subjects who had taken
more ginseng in their lifetime at baseline, this associ-
ation was not statistically significant when confound-
ing factors were adjusted. This discrepant association
of lifetime ginseng intake with cognitive function and
cognitive disorders may be attributable to several fac-
tors. First, the effect of ginseng may improve cogni-
tive function but not prevent or delay cognitive
disorders. Second, the statistical power for testing the
association between ginseng intake and cognitive dis-
orders was smaller than that between ginseng intake
and cognitive function in the current study. Third,
subjective cognitive complaints are required to diag-
nose MCI in addition to objective cognitive impair-
ments [22]. Subjective concerns on objective cognitive
impairments may be different between the groups
classified by the level of ginseng intake.
There are several limitations to this study. First, this
study is subject to recall biases since the use of ginseng
was evaluated using a questionnaire. Second, the dose
effect was not analyzed using the amount of ginseng use,
but was analyzed using the duration of ginseng use.
Ginseng products on the market include varying
amounts of ginseng as an active component (even
though various commercialized ginseng products
provide at most 1 g/day), which makes it difficult to
measure the actual amount of ginseng intake. Third, we
did not adjust for other dietary supplements that could
also influence cognitive function. Lastly, the beneficial
effect of ginseng on cognitive function was shown in the
CERAD total score but not in the MMSE score. Com-
pared to the CERAD Assessment Battery, the MMSE
may be less sensitive to subtle cognitive changes and
more susceptible to the ceiling effect in highly educated,
cognitive normal people [29, 30]. In this study, 6.7% of
the participants achieved a perfect score (30 points) and
35.1% scored 28 points or higher in the MMSE, while no
one achieved a perfect score (100 points) and only 0.3%
scored 91 points or higher in CERAD total score.
Conclusions
Cumulative ginseng use for longer than 5 years may be
beneficial for cognitive function in late life. However, its
effect on the rate of cognitive decline over 4 years in late
life was not observed, which warrants future studies with
longer duration of follow-up.
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